Hydroxyurea-induced onychomadesis in a dog with chronic myeloid leukemia: A case report

Top Companion Anim Med. 2018 Sep;33(3):73-76. doi: 10.1053/j.tcam.2018.06.003. Epub 2018 Jun 12.

Abstract

A 12-year-old Rottweiler dog was presented with a history of prostration, weight loss and hyporexia for six months. Based on complete blood tests (hematological and biochemical analyses), bone marrow examination and imaging analysis, a diagnosis of chronic myeloid leukemia was made. Treatment with hydroxyurea at a dosage of 18 mg/kg twice daily was not effective in controlling the high count of white blood cells. Furthermore, after 35 days of hydroxyurea treatment, the animal developed onycholysis, with sloughing of the claws of the left pelvic and left thoracic limbs and exposure of the distal phalanx. Interruption of the medication was implemented, with clinical healing of the ungual lesions observed three months after initiation of the drug. White blood cells returned to normal after using cyclophosphamide. Currently, the animal is in complete remission, having a disease-free interval of 575 days without chemotherapy. To the authors' knowledge, this is the first report of hydroxyurea-induced onycholysis within a short-term period in a dog diagnosed with chronic myeloid leukemia.

Keywords: Canine; Hydroxycarbamide; Onycholysis.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / therapeutic use
  • Diagnosis, Differential
  • Disease-Free Survival
  • Dog Diseases / blood
  • Dog Diseases / diagnosis*
  • Dog Diseases / drug therapy
  • Dog Diseases / mortality
  • Dogs
  • Female
  • Hydroxyurea / administration & dosage
  • Hydroxyurea / adverse effects
  • Hydroxyurea / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / veterinary*
  • Pedigree
  • Weight Loss

Substances

  • Antineoplastic Agents
  • Cyclophosphamide
  • Hydroxyurea